Blood-Brain Barrier

The blood-brain barrier is the highly selective interface between the bloodstream and the central nervous system, formed chiefly by brain capillary endothelial cells joined by tight junctions and supported by pericytes and astrocyte end-feet. By restricting the free passage of most water-soluble and large molecules and by expressing efflux transporters, it protects the brain's microenvironment while strongly limiting which drugs can reach the central nervous system.

Definition

The blood-brain barrier is a selectively permeable interface, formed by tight-junction-sealed brain capillary endothelium together with pericytes and astrocytes, that regulates the exchange of molecules between blood and brain extracellular fluid and limits the central nervous system penetration of many drugs.

Scope

This topic covers the structure and function of the blood-brain barrier as a determinant of drug distribution: the cellular components of the neurovascular unit, the routes by which molecules do or do not cross, the role of efflux transporters such as P-glycoprotein, and the consequences of these features for central nervous system drug exposure. It treats the barrier as a pharmacokinetic concept and does not provide treatment guidance.

Core questions

• What cellular structures form the blood-brain barrier and give it its selectivity?
• By what routes can molecules cross the barrier, and which physicochemical properties favour crossing?
• How do efflux transporters such as P-glycoprotein limit drug entry into the brain?
• Why does the blood-brain barrier make central nervous system drug delivery a distinctive pharmacokinetic challenge?

Key concepts

• Tight junctions
• Neurovascular unit (endothelium, pericytes, astrocytes)
• Efflux transporters (P-glycoprotein, BCRP)
• Transcellular versus paracellular passage
• Lipophilicity and molecular size as determinants of penetration
• Carrier-mediated and receptor-mediated transport
• CNS drug penetration

Mechanisms

Brain capillary endothelial cells are sealed by continuous tight junctions that block the paracellular diffusion open in most peripheral capillaries, so molecules must cross transcellularly. Small lipophilic drugs can diffuse through the endothelial membranes, while polar nutrients rely on specific carrier-mediated or receptor-mediated transport systems. Even drugs that can enter are often pumped back into the blood by ATP-dependent efflux transporters, of which P-glycoprotein is the prototypical example, acting as a gatekeeper that lowers brain exposure. Pericytes and astrocyte end-feet, together with the endothelium, form a neurovascular unit that induces and maintains these barrier properties.

Clinical relevance

The blood-brain barrier explains why many drugs achieve little or no therapeutic concentration in the brain and why central nervous system drug development must account for barrier penetration and efflux. As a reference concept it informs the interpretation of why some agents act centrally and others do not; it is descriptive and not a basis for individual treatment decisions.

Evidence & guidelines

Understanding of the barrier rests on cell-biological and pharmacological research rather than on clinical trials; reviews synthesising barrier structure, transport, and efflux are the standard reference base.

History

Observations in the late nineteenth and early twentieth centuries that intravenous dyes stained most tissues but spared the brain pointed to a barrier between blood and brain. Electron microscopy later localised the barrier to tight junctions of the brain capillary endothelium, and from the 1990s the discovery that P-glycoprotein and related efflux transporters actively exclude drugs reshaped understanding of central nervous system drug penetration.

Debates

How much does efflux versus passive permeability govern brain penetration?

Brain exposure reflects both passive diffusion across endothelial membranes and active efflux back to blood; the relative weight of these factors for a given drug, and how best to predict net penetration, remains an active modelling question.

Key figures

• N. Joan Abbott
• Alfred Schinkel
• David Begley

Seminal works

• abbott-2006
• abbott-2010
• schinkel-1999

Frequently asked questions

Why can't most drugs cross the blood-brain barrier?

Tight junctions seal the brain capillary endothelium so molecules must pass through the cells rather than between them, and efflux transporters such as P-glycoprotein pump many drugs back into the blood, so only small, lipophilic, non-substrate molecules tend to enter readily.

What is the neurovascular unit?

It is the functional ensemble of brain capillary endothelial cells, pericytes, and astrocyte end-feet that together establish and maintain the barrier's selective permeability.